Klaus Rumpel

机构：Boehringer Ingelheim (Austria) · ORCID：0000-0002-6755-0985

发表论文 72 篇 · 总被引 3812 次 · h-index 29

代表论文

• BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design (2019 · Nature Chemical Biology · 被引 589)
• BI-3406, a Potent and Selective SOS1–KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition (2020 · Cancer Discovery · 被引 432)
• SPR-Measured Dissociation Kinetics of PROTAC Ternary Complexes Influence Target Degradation Rate (2019 · ACS Chemical Biology · 被引 397)
• A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivo (2022 · Nature Communications · 被引 220)
• BacPROTACs mediate targeted protein degradation in bacteria (2022 · Cell · 被引 190)
• Fragment-based discovery of a chemical probe for the PWWP1 domain of NSD3 (2019 · Nature Chemical Biology · 被引 105)